Fiducial Markers

Fiducial Markers Market Outlook

The global fiducial markers market is projected to reach USD 3.2 billion by 2035, growing at a compound annual growth rate (CAGR) of 7.1% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of cancer, which has led to an uptick in radiation therapy and image-guided surgeries, necessitating the use of fiducial markers. Moreover, advancements in healthcare technologies and the rising demand for precise treatment delivery are expected to propel the market forward. Additionally, the growing focus on minimally invasive surgical procedures is driving the adoption of fiducial markers across various applications, including diagnostic imaging and endoscopy. With the ongoing research and development initiatives, the market is poised for significant expansion, offering numerous opportunities for stakeholders.

Growth Factor of the Market

One of the primary growth factors of the fiducial markers market is the increasing incidence of cancer cases globally, which has necessitated more effective treatment modalities such as radiation therapy and image-guided surgery. As these treatment methods often require precise targeting, fiducial markers have become an essential component in ensuring accuracy and efficacy. Moreover, the enhancement of healthcare infrastructure and increasing investment in cancer research are propelling the demand for advanced medical technologies, including fiducial markers. The expanding applications of fiducial markers in various medical disciplines, such as gastroenterology and urology, present additional growth avenues. Furthermore, the rise of outpatient surgical procedures and the emphasis on patient-centric care have created a conducive environment for the adoption of fiducial markers, thereby influencing market growth positively.

Key Highlights of the Market

• The fiducial markers market is anticipated to experience steady growth due to the increasing demand for precision in cancer treatments.
• Technological advancements are expected to enhance the functionality and application scope of fiducial markers.
• Emerging markets are likely to see a rise in the adoption of fiducial markers, driven by improvements in healthcare accessibility.
• Collaboration among medical institutions and research organizations is paving the way for innovative fiducial marker solutions.
• The trend towards minimally invasive surgeries is expected to further boost the market as fiducial markers facilitate these procedures.

By Type

Metallic Fiducial Markers:

Metallic fiducial markers are one of the most commonly used types in various medical applications, especially in radiation therapy. These markers are made from materials such as gold or tungsten, which provide high visibility in imaging techniques due to their radio-opacity. The metallic composition of these fiducial markers allows them to be easily detected during procedures, ensuring precise localization of tumors or targeted treatment areas. Additionally, the durability and stability of metallic markers contribute to their growing preference in clinical settings. As the demand for accurate tumor targeting continues to rise, the market for metallic fiducial markers is expected to witness significant growth during the forecast period.

Radio-opaque Fiducial Markers:

Radio-opaque fiducial markers play a pivotal role in imaging-guided procedures, particularly in radiation therapy, as they assist in accurate tumor localization. These markers are designed to be clearly visible on x-ray or CT scans, allowing for real-time monitoring of treatment progress. Made from materials that absorb radiation effectively, radio-opaque fiducial markers provide enhanced visibility, which aids clinicians in achieving precise alignment during procedures. The increasing adoption of advanced imaging technologies and the growing awareness regarding the importance of accuracy in cancer treatments are expected to drive the demand for radio-opaque fiducial markers in the coming years.

Bio-absorbable Fiducial Markers:

Bio-absorbable fiducial markers have emerged as an innovative alternative to traditional fiducial markers, offering a significant advantage in minimizing post-treatment complications. These markers are designed to dissolve naturally in the body over time, eliminating the need for surgical removal post-procedure. This characteristic makes bio-absorbable fiducial markers particularly appealing in settings where patient comfort and safety are paramount. Their growing acceptance in various medical applications, including radiation therapy and endoscopy, stems from the increasing emphasis on reducing patient invasiveness and improving overall surgical outcomes. As research continues to enhance the efficacy of bio-absorbable materials, their market share is projected to rise.

Ceramic Fiducial Markers:

Ceramic fiducial markers are utilized in applications requiring high stability and biocompatibility. These markers are often preferred in specialized procedures where non-reactive materials are critical to avoid adverse tissue reactions. The inert nature of ceramics ensures that they do not interfere with the body’s biological processes, making them suitable for long-term applications. Their durability and ability to withstand high radiation doses allow them to be employed in radiation therapy effectively. As healthcare providers increasingly prioritize biocompatibility and patient safety, the demand for ceramic fiducial markers is expected to grow steadily in the market.

Others:

The "Others" category encompasses a range of fiducial marker types that may not fit the conventional classifications but still serve critical roles in specialized medical applications. This includes markers made from various polymers or composites that offer unique advantages, such as enhanced flexibility or specific imaging characteristics. As the market evolves, emerging technologies are likely to introduce new materials and innovations within this category, catering to niche applications that require tailored solutions. The continuous exploration of diverse materials and designs is expected to keep this segment dynamic, contributing to overall market growth.

By Application

Radiation Therapy:

Radiation therapy is one of the primary applications driving the fiducial markers market. With the increasing incidence of cancer worldwide, radiation therapy is often employed as a crucial treatment option. Fiducial markers are utilized to ensure precise tumor localization and accurate radiation delivery, minimizing damage to surrounding healthy tissues. The adoption of advanced imaging technologies has further enhanced the need for fiducial markers, as they facilitate real-time tracking and monitoring during treatment sessions. As healthcare providers continually seek improved therapeutic outcomes, the reliance on fiducial markers in radiation therapy is expected to grow stronger, leading to an expanded market share.

Image-guided Surgery:

Image-guided surgery is a rapidly evolving field that incorporates advanced imaging techniques to enhance surgical precision. Fiducial markers play a vital role in this application by providing clear reference points for surgeons, ensuring accurate navigation during procedures. The integration of fiducial markers into surgical workflows allows for improved visualization of anatomical structures, ultimately leading to better surgical outcomes. As the demand for minimally invasive surgical procedures rises, the significance of fiducial markers in image-guided surgeries is anticipated to increase, further propelling market growth.

Endoscopy:

In endoscopy, fiducial markers serve as valuable tools for enhancing procedural accuracy and ensuring optimal treatment delivery. These markers can be placed during endoscopic procedures to provide reference points for later imaging or therapeutic interventions. The use of fiducial markers in endoscopy is growing as healthcare professionals strive to improve patient outcomes and streamline procedures. Furthermore, advancements in endoscopic technologies are expected to drive the adoption of fiducial markers, as they enable more complex and precise interventions. The ongoing evolution of endoscopic practices will likely bolster the fiducial markers market in this application area.

Diagnostic Imaging:

Fiducial markers are also increasingly utilized in diagnostic imaging to enhance the accuracy of imaging techniques such as MRI and CT scans. By providing clear localization points, these markers allow radiologists to focus on specific anatomical areas of interest, improving the overall quality of diagnostic evaluations. The integration of fiducial markers in diagnostic imaging is particularly beneficial in cancer detection and treatment planning, as it enables better visualization of tumors and surrounding structures. As healthcare providers continue to emphasize the importance of accurate diagnostics, the demand for fiducial markers in this application is expected to rise significantly.

Others:

The "Others" category in application includes fiducial marker usage in specialized areas such as research and experimental procedures. These applications may involve novel techniques or specific conditions requiring tailored fiducial marker solutions. The ongoing exploration of fiducial markers beyond conventional applications is likely to lead to innovative use cases, thereby expanding their market presence. As research continues to unveil new opportunities for fiducial markers, this segment is expected to contribute to the overall growth of the fiducial markers market.

By User

Hospitals:

Hospitals represent a significant end-user segment for fiducial markers, owing to their comprehensive healthcare services and advanced treatment modalities. As leading centers for cancer treatment, hospitals increasingly utilize fiducial markers in radiation therapy and image-guided surgeries, ensuring accurate tumor localization and treatment delivery. The presence of specialized oncology departments and access to advanced imaging technologies further bolsters the demand for fiducial markers within hospital settings. With the continuous rise in cancer diagnoses and treatment complexities, hospitals are expected to remain key players in the fiducial markers market.

Specialty Clinics:

Specialty clinics focusing on oncology and surgical services are also crucial users of fiducial markers. These clinics often employ advanced treatment methods that require precise localization techniques, making fiducial markers essential for their procedures. The growing trend towards outpatient services and personalized treatment plans in specialty clinics is driving the demand for fiducial markers, as they facilitate more effective and targeted interventions. With the increasing number of specialty clinics emerging globally, this segment is poised for substantial growth within the fiducial markers market.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming increasingly important in the fiducial markers market due to the rising preference for outpatient procedures. These centers often perform minimally invasive surgeries that require precise localization, thus necessitating the use of fiducial markers. The convenience and cost-effectiveness offered by ASCs make them an attractive option for patients, leading to a significant increase in the volume of procedures performed. As the trend of outpatient care continues to grow, the demand for fiducial markers in ambulatory surgical centers is expected to increase, further contributing to market expansion.

Cancer Research Institutes:

Cancer research institutes play a vital role in the fiducial markers market by driving innovation and advancing treatment methodologies. These institutes often engage in clinical trials and research studies that explore new applications for fiducial markers, thereby contributing to their development and integration into clinical practices. The collaboration between research institutions and healthcare providers fosters the continuous evolution of fiducial marker technologies, enhancing their efficacy and utility in cancer treatment. As research initiatives expand, the involvement of cancer research institutes will likely lead to increased adoption and utilization of fiducial markers in the market.

Others:

The "Others" category encompasses various end-users that utilize fiducial markers in specialized applications or settings. This may include veterinary practices, academic research laboratories, or other healthcare facilities that require precise localization techniques. As awareness regarding the benefits of fiducial markers spreads across diverse medical fields, this segment is expected to grow. Innovations in fiducial marker technologies may open new avenues for their application, leading to expanded usage among varied end-user categories.

By Material

Gold:

Gold fiducial markers are well-regarded for their biocompatibility and radio-opacity, making them ideal for various medical applications, particularly in radiation therapy. The high visibility of gold markers in imaging techniques allows for precise tumor localization, ensuring accurate treatment delivery. Additionally, gold markers are resistant to corrosion and can withstand high radiation doses, making them a preferred choice in clinical settings. The ongoing demand for effective cancer treatment solutions is expected to drive the growth of gold fiducial markers in the market.

Tungsten:

Tungsten fiducial markers are gaining popularity due to their exceptional density and radio-opacity, making them highly effective in imaging applications. These markers provide excellent visibility during imaging procedures, allowing for accurate tumor targeting and treatment delivery. Furthermore, tungsten's durability ensures that the markers remain stable during the treatment process, contributing to their reliability in clinical use. As healthcare providers increasingly prioritize accuracy in cancer treatments and imaging, the demand for tungsten fiducial markers is anticipated to rise.

Silicone:

Silicone fiducial markers offer significant advantages in terms of flexibility and biocompatibility, making them suitable for various medical applications. These markers can be easily molded into different shapes and sizes, allowing for customized solutions tailored to specific procedural requirements. The biocompatible nature of silicone reduces the risk of adverse reactions in patients, enhancing overall safety during procedures. As the demand for patient-centered care continues to grow, the utilization of silicone fiducial markers is expected to increase in the market.

Iodine:

Iodine fiducial markers are utilized primarily in imaging-guided procedures due to their radio-opacity and low toxicity. These markers are designed to be easily visualized during imaging, aiding clinicians in accurate tumor localization. The use of iodine markers is particularly advantageous in settings where non-invasive techniques are preferred. The growing emphasis on precision medicine and minimally invasive procedures is expected to drive the adoption of iodine fiducial markers as healthcare providers seek innovative solutions for improved patient outcomes.

Others:

The "Others" category in material encompasses a range of fiducial markers made from various polymers, composites, or novel materials that offer unique properties for specialized applications. These alternative materials may provide specific benefits, such as enhanced visibility, flexibility, or biodegradability. As technological advancements continue to introduce innovative materials into the market, the "Others" segment is likely to expand as healthcare providers explore diverse solutions for fiducial marker applications. This ongoing evolution in materials is expected to contribute to the overall growth of the fiducial markers market.

By Region

The North American region is expected to dominate the fiducial markers market, accounting for approximately 40% of the overall market share by 2035. This dominance can be attributed to the presence of advanced healthcare infrastructure, a high prevalence of cancer cases, and significant investments in medical research and development. The increasing adoption of innovative treatment modalities and imaging technologies further fuels the growth of the fiducial markers market in this region. Additionally, the collaboration between healthcare providers and research institutions enhances the development and utilization of fiducial markers, solidifying North America's leading position in the market.

Europe is anticipated to hold a substantial share of the fiducial markers market, with a projected CAGR of 6.5% during the forecast period. The growing emphasis on precision medicine and the rising number of cancer cases across European countries contribute to the market's growth in this region. Furthermore, advancements in healthcare technologies and an increasing number of research initiatives focusing on cancer treatments are expected to drive the demand for fiducial markers. As European healthcare systems continue to evolve and prioritize innovative solutions, the fiducial markers market in the region is likely to witness steady expansion.

Opportunities

The fiducial markers market presents a multitude of opportunities driven by the increasing demand for innovative cancer treatment solutions. As the global incidence of cancer continues to rise, there is a growing need for precise localization techniques to enhance treatment outcomes. Healthcare providers are actively seeking advanced technologies that improve treatment efficacy while minimizing side effects. This demand creates an opportunity for manufacturers to develop next-generation fiducial markers with enhanced features such as bio-absorption, improved visibility, and customizable options. Furthermore, the expansion of outpatient surgical centers and specialty clinics is also paving the way for increased adoption of fiducial markers, thereby fostering growth in the market. Additionally, collaborations between research institutions and industry players may lead to the introduction of groundbreaking fiducial marker solutions that cater to specific clinical needs.

Another promising opportunity within the fiducial markers market is the growing emphasis on personalized medicine. As cancer treatment shifts towards more individualized approaches, the demand for precise and tailored solutions is expected to surge. Fiducial markers can play a crucial role in facilitating personalized treatment plans by enabling accurate tumor localization and treatment monitoring. Furthermore, the adoption of telemedicine and remote monitoring technologies may open new avenues for fiducial marker applications, allowing for real-time tracking of patient progress and treatment efficacy. As healthcare continues to evolve, the fiducial markers market is poised for significant growth, driven by the adoption of innovative solutions that address the changing needs of patients and healthcare providers.

Threats

Despite the promising growth potential of the fiducial markers market, certain threats may impede its progress. One of the primary concerns is the stringent regulatory environment governing medical devices. The approval processes for new fiducial marker technologies can be lengthy and complex, potentially delaying the introduction of innovative solutions to the market. Additionally, the high costs associated with research and development, coupled with the need for compliance with various regulatory standards, may deter smaller manufacturers from entering the market. Furthermore, the competition from alternative localization techniques, such as imaging biomarkers and navigation systems, poses a threat to the widespread adoption of fiducial markers in clinical settings. As healthcare providers explore various options for tumor localization, the fiducial markers market must continuously innovate to remain competitive and address these challenges effectively.

Another significant threat to the fiducial markers market is the risk of adverse patient reactions associated with certain types of fiducial markers. While many fiducial markers are designed to be biocompatible, there is still a possibility of complications arising from their use. Patient safety concerns may lead to hesitancy among healthcare providers when considering fiducial markers for specific applications. Additionally, the rising trend of minimally invasive procedures may shift the focus away from fiducial markers as alternatives gain traction. To mitigate these threats, manufacturers must prioritize research and development efforts focused on enhancing the safety and efficacy of fiducial markers while also addressing the evolving needs of the healthcare landscape.

Competitor Outlook

• Varian Medical Systems
• RaySearch Laboratories AB
• Boston Scientific Corporation
• AccuRay Incorporated
• Cianna Medical
• IBA Radiopharma Solutions
• Medtronic
• Mevion Medical Systems
• Elekta AB
• CIVCO Medical Solutions
• Nanobiotix
• OncoOne
• Qfix Systems
• NorthStar Medical Radioisotopes
• Hologic, Inc.

The competitive landscape of the fiducial markers market is characterized by the presence of several established players and emerging companies vying for market share. Major companies such as Varian Medical Systems, Boston Scientific Corporation, and Elekta AB dominate the market, leveraging their extensive product portfolios and advanced technologies to meet the growing demand for fiducial markers. These companies invest significantly in research and development initiatives, focusing on innovative solutions that enhance the accuracy and reliability of fiducial markers in various medical applications. Additionally, collaborations and partnerships among industry players are becoming increasingly common, allowing them to combine expertise and resources to accelerate product development and expand their market reach.

Varian Medical Systems, a leader in radiation oncology, offers a wide range of fiducial markers tailored for various applications, including prostate cancer treatment. The company's commitment to innovation is evident in its continuous efforts to develop new fiducial marker technologies that improve treatment precision. Similarly, Boston Scientific Corporation specializes in medical devices across multiple specialties, including oncology, and has introduced several fiducial marker products that enhance imaging capabilities. With a strong focus on patient-centric solutions, these companies aim to address the growing needs of healthcare providers in delivering effective cancer treatments.

Emerging players such as Nanobiotix and OncoOne are also making their mark in the fiducial markers market by introducing innovative solutions that cater to specific treatment requirements. Nanobiotix focuses on the development of nanomedicine-based fiducial markers that enhance the effectiveness of radiation therapy. Their novel approach aims to improve patient outcomes by delivering targeted treatment while minimizing side effects. OncoOne, on the other hand, is leveraging advanced imaging technologies to create fiducial markers that offer improved visibility and localization during procedures. These emerging companies are poised to disrupt the market landscape by offering cutting-edge solutions that address the evolving demands of the healthcare sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 OncoOne
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Elekta AB
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Nanobiotix
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Qfix Systems
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Hologic, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Cianna Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AccuRay Incorporated
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Mevion Medical Systems
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Varian Medical Systems
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 CIVCO Medical Solutions
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 IBA Radiopharma Solutions
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 RaySearch Laboratories AB
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Boston Scientific Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 NorthStar Medical Radioisotopes
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Fiducial Markers Market, By Type
    • 6.1.1 Metallic Fiducial Markers
    • 6.1.2 Radio-opaque Fiducial Markers
    • 6.1.3 Bio-absorbable Fiducial Markers
    • 6.1.4 Ceramic Fiducial Markers
    • 6.1.5 Others
  • 6.2 Fiducial Markers Market, By user
    • 6.2.1 Hospitals
    • 6.2.2 Specialty Clinics
    • 6.2.3 Ambulatory Surgical Centers
    • 6.2.4 Cancer Research Institutes
    • 6.2.5 Others
  • 6.3 Fiducial Markers Market, By Material
    • 6.3.1 Gold
    • 6.3.2 Tungsten
    • 6.3.3 Silicone
    • 6.3.4 Iodine
    • 6.3.5 Others
  • 6.4 Fiducial Markers Market, By Application
    • 6.4.1 Radiation Therapy
    • 6.4.2 Image-guided Surgery
    • 6.4.3 Endoscopy
    • 6.4.4 Diagnostic Imaging
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Fiducial Markers Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Fiducial Markers market is categorized based on

By Type

• Metallic Fiducial Markers
• Radio-opaque Fiducial Markers
• Bio-absorbable Fiducial Markers
• Ceramic Fiducial Markers
• Others

By Application

• Radiation Therapy
• Image-guided Surgery
• Endoscopy
• Diagnostic Imaging
• Others

By user

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Cancer Research Institutes
• Others

By Material

• Gold
• Tungsten
• Silicone
• Iodine
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Varian Medical Systems
• RaySearch Laboratories AB
• Boston Scientific Corporation
• AccuRay Incorporated
• Cianna Medical
• IBA Radiopharma Solutions
• Medtronic
• Mevion Medical Systems
• Elekta AB
• CIVCO Medical Solutions
• Nanobiotix
• OncoOne
• Qfix Systems
• NorthStar Medical Radioisotopes
• Hologic, Inc.